Prescribing preferences in rapid tranquillisation: a survey in Belgian psychiatrists and emergency physicians by unknown
Bervoets et al. BMC Res Notes  (2015) 8:218 
DOI 10.1186/s13104-015-1172-2
RESEARCH ARTICLE
Prescribing preferences in rapid 
tranquillisation: a survey in Belgian psychiatrists 
and emergency physicians
Chris Bervoets1,2*, Ella Roelant1,3, Jürgen De Fruyt4, Hella Demunter5, Barry Dekeyser6, Leen Vandenbussche7, 
Koen Titeca8, Guido Pieters1,5, Bernard Sabbe1,9 and Manuel Morrens1,10
Abstract 
Background: The pharmacotherapeutic management of agitation is a common clinical challenge. Pharmacotherapy 
is frequently used, the use of published guidelines is not known. The purpose of this study was twofold; to describe the 
prescribing patterns of psychiatrists and emergency physicians and to evaluate to which extent guidelines are used.
Methods: A cross-sectional survey in the Dutch-speaking part of Belgium is carried out in 39 psychiatric hospitals, 
11 psychiatric wards of a general hospital and 61 emergency departments. All physicians are asked for demographic 
information, their prescribing preferences, their use of guidelines and the type of monitoring (effectiveness, safety). 
For the basic demographic data and prescription preferences descriptive statistics are given. For comparing prescrib-
ing preferences of the drug between groups Chi square tests (or in case of low numbers Fisher’s exact test) were 
performed. Mc Nemar test for binomial proportions for matched-pair data was performed to see if the prescription 
preferences of the participants differ between secluded and non-secluded patients.
Results: 550 psychiatrist and emergency physicians were invited. The overall response rate was 20% (n = 108). The 
number 1 preferred medication classes were antipsychotics (59.3%) and benzodiazepines (40.7%). In non-secluded 
patients, olanzapine (22.2%), lorazepam (21.3%) and clotiapine (19.4%) were most frequently picked as number 1 
choice drug. In secluded patients, clotiapine (21.3%), olanzapine (21.3%) and droperidol (14.8%) were the three most 
frequently chosen number 1 preferred drugs. Between-group comparisons show that emergency physicians prefer 
benzodiazepines significantly more than psychiatrists do. Zuclopenthixol and olanzapine show a particular profile 
in both groups of physicians. Polypharmacy is more frequently used in secluded patients. Published guidelines and 
safety or outcome monitoring are rarely used.
Conclusions: Our results show that prescription practice in Flanders (Belgium) in acute agitation shows a complex 
relationship with published guidelines. Prescription preferences differ accordingly to medical specialty. These findings 
should be taken into account in future research.
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Background
Agitated behaviour during a hospital admission is a fre-
quently encountered problem. It is estimated that yearly 
1.7 million hospital admissions occur due to agitation 
[1,  2]. About 10% of the patients admitted to the emer-
gency department are at risk of developing agitation symp-
toms [3]. Agitation is seen in conjunction with different 
psychiatric and non-psychiatric medical conditions [4–6].
Although motor restlessness, increased responsive-
ness to stimuli, irritability, inappropriate and usually 
purposeless verbal and motor activity are reported as the 
major hallmarks of the syndrome, there is no consensus 
regarding the symptoms that constitute agitation. Little 
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is known about its course over time and which level of 
agitation should lead to pharmacological treatment [7, 8]. 
This ambiguities all hamper the development of general-
izable clinical guidelines [9]. Although good clinical trials 
have been conducted to investigate the effectiveness and 
the safety of drugs prescribed in agitated behaviour [10–
12], results should be interpreted cautiously in clinical 
practice, given that these trials have better internal than 
ecological validity [13–15]. Consequently, prescribing 
preferences may not always be based on evidence based 
guidelines, although the use of drugs in this indication is 
widely spread [1, 2, 9, 15].
In order to map prescribing habits of physicians in 
acute agitation, a series of studies—surveying physicians’ 
preferences—was conducted between 1999 and 2004 
[10, 12, 16–20]. While they all differ in methodological 
design, do not compare between psychiatrists and emer-
gency physicians, and are all service-specific or region 
specific, a few trends can be found in these reports. 
Firstly, antipsychotics (olanzapine, haloperidol and dro-
peridol) and benzodiazepines (diazepam, lorazepam) are 
the preferred drugs of choice. Secondly, there is no real 
preference for peroral or intramuscular administration. 
Thirdly, there is a reported trend in favour of using com-
binations of drugs.
The present study was conducted with a twofold 
objective. We firstly aimed to describe the prescribing 
preferences and their between group differences of psy-
chiatrists and emergency physicians in Belgium in the 
management of acute agitation and secondly we evalu-
ated to which extend prescribing preferences were in 
accordance with published treatment guidelines.
Methods
A cross-sectional online survey was carried between 
the July 2012 and September 2012 in 39 psychiatric hos-
pitals, 11 psychiatric wards of a general hospital and 
61 emergency departments. 281 psychiatrists and 267 
emergency physicians received an invitation to respond 
to the survey. Participating psychiatrists and emergency 
physicians were asked to give demographic and profes-
sional information, describe their prescribing habits in 
the treatment of acute agitation, their use of evidence 
based guidelines and the type of monitoring (effective-
ness, safety) they provide for their patients. Agitation was 
defined in the survey as a clinical condition with acute 
onset of psychomotor and emotional excitement. The fol-
lowing parameters were collected: age, gender, medical 
specialty, medical setting, number of patients with agita-
tion admitted in 1 month, use of rating scales, preference 
of drug prescribed, use of drugs in combinations, effect 
of seclusion on prescription preference, use of guidelines 
and modalities of monitoring of efficacy as well as patient 
safety.
First, it was evaluated which medication classes and 
specific drugs were preferred and if preferences changed 
in the case the patient needed seclusion. Second, we 
looked for differences in prescribing habits depending on 
the medical specialty.
For the basic demographic data and prescription pref-
erences descriptive statistics are given. For each drug, 
two Chi square tests (or in case of low numbers Fisher’s 
exact test) were performed, one comparing prescribing 
preferences of the drug between psychiatrists and emer-
gency physicians and another one comparing prescribing 
preferences between age groups. Mc Nemar test for bino-
mial proportions for matched-pair data was performed 
to see if the prescription preferences of the participants 
differ between secluded and non-secluded patients. 
IBM SPSS Statistics version 20.0 was used for statistical 
analyses.
Results
Response rate and respondents characteristics
110 psychiatrists and emergency physicians responded 
to the online survey, yielding a response rate of 20%. 
Two of them were removed from further analysis as they 
reported treating 0 patients per month for agitation. 
From the 108 respondents, 69 (63.9%) were male and 39 
(36.1%) were female. Psychiatrist accounted for 65.7%, 
emergency physicians for 34.3%. Sixty-seven respond-
ents were between the ages of 25 and 45 years of age, 41 
respondents were older than 45 years. Physicians worked 
in different settings; 42 (38.9%) in a psychiatric hospi-
tal, 25 (23.1%) in a psychiatric ward of a general hospi-
tal and 41 (38.0%) in an emergency service. A caseload 
for agitation between 1 and 10 patients per month was 
reported by 69 (63.9%) of the participants, 23 (21.3%) had 
a monthly caseload between 11 and 20 and 16 (14.8%) 
reported a caseload higher than 20 patients.
Preferences in medication prescriptions
General preferences for a medication class in acute agitation
Respondents were asked to point out which of five medi-
cation classes (antipsychotics, antidepressants, benzo-
diazepines, mood stabilizers and antihistaminics) they 
favoured in the treatment of acute agitation. They had to 
give the classes a number from 1 to 5 with 1 being the 
most preferred class, 2 the second preferred class,… All 
respondents chose either antipsychotics (59.3%) or ben-
zodiazepines (40.7%) as their number 1 preferred medi-
cation. As a number 2 medication class benzodiazepines 
were most preferred (54.6%). The number 3 medication 
class that was most popular are the mood stabilizers 
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(37.4%), number 4 are the antidepressants (38.3%) and 
number 5 are the antihistaminics (44.9%).
Rankings for all medication classes are shown in 
Table 1.
Prescribing preferences in non‑secluded patients
All participants were given a list of 80 drugs and were 
asked to select their 3 most used drugs when consider-
ing all patients in need for a treatment of agitation and 
rank these according to preference, rank 1 being their 
first choice drug. All rankings are listed in Table 2. Olan-
zapine (22.2%), lorazepam (21.3%) and clotiapine (19.4%) 
were the three most popular first choice drugs. Most fre-
quent ranked second were lorazepam (21.3%), olanzapine 
(17.6%) and droperidol (12.0%). As a third choice, clo-
tiapine (13%), lorazepam (11.1%) and olanzapine (11.1%) 
were reported most frequently. Although zuclopenthixol 
does not appear but in third choice (2.8%), the long acting 
formula of this drug is reported more frequently (1.9% as 
first choice; 2.8% as second choice; 8.3% as third choice).
Of the participants 107 answered the question on the 
use of monotherapy versus combinations, 21.5% of them 
reported to use only monotherapy whilst 67.3% use a 
combination of drugs in a step-up regimen and 11.2% a 
combination of drugs from the start of the treatment.
Prescribing preferences in secluded patients
We also investigated what the prescription preferences 
were when patients were considered that are in need of 
a seclusion room as a non-pharmacological approach 
to agitation. 62% of the participants adapt their drug 
choice (38% of participants reported not to change 
their prescription preferences in this type of patients). 
Participants were asked to give their top 3 drugs for 
secluded patients from the same list of 80 drugs (rank-
ings are shown in Table 2). Clotiapine (21.3%), olanzap-
ine (21.3%) and droperidol (14.8%) were reported the 
most frequently as first choice. Most frequently ranked 
second were lorazepam (22.2%), diazepam (13.9%) and 
clotiapine (12.0%). Most mentioned number 3 drugs 
were lorazepam (13.0%), haloperidol (12.0%), clotiapine 
(10.2%), droperidol (10.2%) and zuclopenthixol long for-
mula (10.2%). Again, zuclopenthixol does not appear but 
as third choice (3.7%). However, the long acting formula 
of this drug is reported more frequently than in the non-
secluded group of patients (6.5; 3.7; 10.2%).
For the treatment of secluded patients 107 respondents 
answered the question on the use of monotherapy versus 
combinations. 15.9% reported to use only monotherapy 
whilst 59.8% use a combination of drugs in a step-up reg-
imen and 24.3% a combination of drugs from the start of 
the treatment.
Differences in medication preferences for psychiatrists 
and emergency physicians
For non-secluded patients all participants ranked either 
antipsychotics or benzodiazepines as their first choice 
used drugs, we use a Chi square test to see if there is a 
difference between first choice use among psychia-
trists and emergency physicians. Only 19 of the 71 psy-
chiatrists (26.8%) classified benzodiazepines as their 
preferred product whereas 25 of the 37 emergency phy-
sicians (67.6%) did so. This difference in preference was 
significant (Chi square test p < 0.001).
No differences in preference between psychiatrists and 
emergency physicians was found for conventional antip-
sychotics (clothiapine, droperidol, haloperidol, zuclopen-
thixol en zuclopenthixol long acting) (psychiatrists; 27 
(38%) and emergency physicians; 10 (27%); Chi square 
test p = 0.253) but a significant difference was found for 
atypical antipsychotics (aripiprazole, olanzapine, risperi-
done, quetiapine) (psychiatrists; 27 (38%) and emergency 
physicians; 7 (18.9%); Chi square test p  =  0.042). The 
analysis of differences in preference for specific drugs 
in non-secluded patients are listed in Table  3. The first 
three columns use for the considered drug the criterium: 
did the participant rank this as number 1 drug? The last 
3 columns use as criterium: did the participant put this 
drug in its top 3? The number of positive answers to this 
criterium together with the percentages of either pro-
fessional group are given. A Fisher’s exact test was per-
formed for each drug. Psychiatrists place quetiapine and 
zuclopenthixol (long acting formula) significantly more 
than emergency physicians in their top 3 of used drugs. 
In contrast, midazolam, diazepam and haloperidol are 
significantly more in the top 3 of emergency physicians.
In secluded patients, psychiatrists [n  =  12 (16.9%)] 
classified a benzodiazepine as their preferred prod-
uct whereas this was significantly higher in the emer-
gency physicians group [n = 18 (48.6%)]; Chi square test 
p < 0.001).
A significant difference was found in preference 
between psychiatrists and emergency physicians for 
Table 1 Overview of number 1–5 preferred medication 
classes
AP antipsychotics, BZD benzodiazepines, AD antidepressants, MS mood stabiliz-
ers, AH antihistaminics.
AP BZD AD MS AH
59.3 40.7 0 0 0
40.7 54.6 1.9 1.9 0.9
0 1.9 31.8 37.4 29.0
0 1.9 38.3 34.6 25.2
0 0.9 28.0 26.2 44.9
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conventional antipsychotics (psychiatrists; 39 (54.9%) 
and emergency physicians; 11 (29.7%); Chi square test 
p =  0.013) but this was not the case for atypical antip-
sychotics (psychiatrists; 20 (28.2%) and emergency physi-
cians; 7 (18.9%); Chi square test p = 0.292). The analysis 
of differences in preference for specific drugs in secluded 
patients are listed in Table 4 analogously to Table 3. Psy-
chiatrists place olanzapine, zuclopenthixol (long acting 
formula) and quetiapine significantly more in their top 3 
than emergency physicians. In contrast, diazepam, halo-
peridol and midazolam, are placed in the top 3 signifi-
cantly more amongst emergency physicians.
Differences in medication preferences for age‑groups
The total sample of respondents was splitted into a 
group of prescribers that was younger than 45  years of 
age (n = 67, 62%) and a group older than 45 years of age 
(n = 41, 38.0%). When non-secluded patients were to be 
considered by the respondents, it was found that older 
physicians (n  =  6) tended to prefer droperidol as their 
number 1 choice drug over their younger peers (n =  1, 
Fisher’s exact p =  0.012) whereas a trend was observed 
for lorazepam as number 1 choice drug in favour of the 
younger physicians (n =  18) versus older peers (n =  5, 
p = 0.091). Further, no significant age effect on prescrip-
tion preferences was found for all other drugs. When 
secluded patients were to be considered by the respond-
ents, no significant effect for doctor’s age was observed 
except for zuclopenthixol long formula in the top 3 
of favourite drugs which was preferred by older peers 
(n =  15) versus younger physicians (n =  7, p =  0.002). 
The same trend as seen for lorazepam as number 1 
Table 2 Prescribing preferences in non-secluded and secluded patients
LA long acting.
Drug Non-secluded patients Secluded patients
Rank 1 Rank 2 Rank 3 Rank 1 Rank 2 Rank 3
Frequency % Frequency % Frequency % Frequency % frequency % Frequency %
Alprazolam 2 1.9 5 4.6 1 0.9 1 0.9 4 3.7
Alprazolam (LA) 1 0.9
Amisulpiride 1 0.9
Aripiprazole 3 2.8 1 0.9 3 2.8 4 3.7 1 0.9
Bromazepam 1 0.9 1 0.9
Clonazepam 1 0.9 2 1.9
Clorazepaat 4 3.7 5 4.6 7 6.5 4 3.7 6 5.6 7 6.5
Clotiapine 21 19.4 8 7.4 14 13 23 21.3 13 12.0 11 10.2
Cloxazolam 1 0.9
Diazepam 5 4.6 10 9.3 5 4.6 6 5.6 15 13.9 5 4.6
Droperidol 7 6.5 13 12 8 7.4 16 14.8 12 11.1 11 10.2
Escitalopram 1 0.9 1 0.9
Haloperidol 7 6.5 3 2.8 10 9.3 4 3.7 7 6.5 13 12.0
Lamotrigine 1 0.9
Lorazepam 23 21.3 23 21.3 12 11.1 14 13 24 22.2 14 13
Midazolam 2 1.9 2 1.9 2 1.9 2 1.9 3 2.8 2 1.9
Olanzapine 24 22.2 19 17.6 12 11.1 23 21.3 12 11.1 8 7.4
Paliperidone 1 0.9 1 0.9
Pipamperone 3 2.8 1 0.9 2 1.9
Prazepam 1 0.9 1 0.9
Promethazin 1 0.9 1 0.9 3 2.8
Quetiapine 5 4.6 12 11.1 5 4.6 3 2.8 6 5.6 3 2.8
Risperidone 2 1.9 2 1.9 3 2.8 1 0.9 2 1.9
Trazodone 1 0.9
Sodium valproate 1 0.9 4 3.7 1 0.9 2 1.9
zuclopenthixol 3 2.8 4 3.7
zuclopenthixol (LA) 2 1.9 3 2.8 9 8.3 7 6.5 4 3.7 11 10.2
Total 108 100 108 100 108 100 108 100 108 100 108 100
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choice drug in the non-secluded patients was noticed for 
secluded patients (p =  0.075, with n =  12 younger and 
n = 2 older physicians).
Which drug preferences are most likely to be affected by a 
seclusion?
In order to detect if a drug preference was signifi-
cantly altered when considering seclusion status of 
the patient a McNemar test for binomial proportions 
for matched-pair data was performed. If we consider 
the drugs that were picked as number 1 and compare 
this preference between secluded and non-secluded 
patients then droperidol is more preferred in the 
secluded patients (p  =  0.022) and lorazepam in the 
non-secluded patients (p = 0.022). If we consider pref-
erence as placing this drug in the top 3 we found that 
droperidol (p  =  0.003) and zuclopenthixol long for-
mula (p  =  0.039) are preferred in secluded patients 
and olanzapine (p = 0.012) and quetiapine (p = 0.006) 
in non-secluded patients.
Use of guidelines and monitoring for efficacy and safety
Guidelines are not frequently used. Only 29 respondents 
(26.9%) report the use of guidelines. Of these 29, 62.1% 
use local guidance or recommendations, 17.2% a recom-
mendation issued by a national professional society or 
20.7% a published guideline. The majority of respondents 
(97.2%) uses only clinical response evaluations to moni-
tor the effect of the rapid tranquillisation. There is no use 
of physical monitoring.
Discussion
Agitation is a regularly encountered clinical condition 
by psychiatrists as well as by emergency physicians since 
64% of the respondents have up to ten cases per month in 
treatment and 21% up to twenty cases per month.
The results of this study show that there is no clear 
or systematic rationale for prescribing for acute agita-
tion in Belgium. In this respect, variability in practice 
in Belgium is comparable to other countries [21]. This is 
the most important finding since considerable risks (use 
Table 3 Between group differences in non-secluded patients
Fisher’s exact test was performed when one of the two groups had at least two counts (two-sided).













Alprazolam LA 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Alprazolam 1 (1.4) 1 (2.7) 1.000 4 (5.6) 3 (8.1) 0.689
Aripiprazole 3 (4.2) 0 (0) 0.55 7 (9.9) 0 (0) 0.093
Bromazepam 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Clonazepam 0 (0) 0 (0) – 0 (0) 1 (2.7) –
Clorazepaat 2 (2.8) 2 (5.4) 0.605 9 (12.7) 7 (18.9) 0.404
Clotiapine 17 (23.9) 4 (10.8) 0.128 28 (39.4) 15 (40.5) 1.000
Diazepam 0 (0) 5 (13.5) 0.004 3 (4.2) 17 (45.9) <0.001
Droperidol 5 (7.0) 2 (5.4) 1.000 17 (23.9) 11 (29.7) 0.644
Escitalopram 0 (0) 0 (0) – 0 (0) 2 (5.4) 0.115
Haloperidol 3 (4.2) 4 (10.8) 0.228 6 (8.5) 14 (37.8) <0.001
Lorazepam 14 (19.7) 9 (24.3) 0.625 43 (60.6) 15 (40.5) 0.067
Midazolam 0 (0) 2 (5.4) 0.115 0 (0) 6 (16.2) 0.001
Olanzapine 17 (23.9) 7 (18.9) 0.631 40 (56.3) 15 (40.5) 0.156
Paliperidone 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Pipamperone 0 (0) 0 (0) – 3 (4.2) 1 (2.7) 1.000
Prazepam 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Promethiazine 0 (0) 0 (0) – 0 (0) 1 (2.7) –
Quetiapine 5 (7.0) 0 (0) 0.163 22 (31) 0 (0) <0.001
Risperidone 2 (2.8) 0 (0) 0.545 6 (8.5) 1 (2.7) 0.418
Trazodone 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Sodium Valproate 0 (0) 1 (2.7) – 4 (5.6) 1 (2.7) 0.659
Zuclopenthixol 0 (0) 0 (0) – 2 (2.8) 1 (2.7) 1.000
Zuclopenthixol LA 2 (2.8) 0 (0) 0.545 14 (19.7) 0 (0) 0.002
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of physical restraint, cardiovascular severe side effects, 
higher likelihood of high dose prescribing and polyphar-
macy) are attached to prescribing in acute agitation with-
out clear and evidence based rationale.
Antipsychotics are ranked most often first choice and 
benzodiazepines second choice when all respondents 
in the survey are considered. In non-secluded patients, 
preference is given to olanzapine, lorazepam and clo-
tiapine. In secluded patients, who arguably demonstrate 
higher degrees of agitation compared to non-secluded 
patients, clotiapine, olanzapine and droperidol are pre-
scribed the most. The preference of droperidol is of par-
ticular interest since this drug has been banned from use 
in North America and the UK because of concerns over 
its cardiotoxicity, more specifically the significant length-
ening of the QTc interval in certain patients [22]. Again, 
this finding illustrates the lack of international evidence 
based rationale in guiding the treatment of agitation. A 
recent consensus statement of the psychopharmacology 
workgroup of the American Association for Emergency 
Psychiatry [23] recommended antipsychotics—and in 
particular olanzapine or risperidone—as first-line man-
agement of acute agitation. However, this consensus 
statement does not differentiate patients according to 
their level of agitation, as is the case in our study. On 
the basis of a non-systematical review of the literature, 
Bak et al. [24] also advise for olanzapine and lorazepam, 
although the authors recommend to use lorazepam only 
in non-psychotic agitation. In addition, in a review of the 
literature in the period 1960–2000 by Battaglia et al. [25], 
it was found that most evidence for a safe and effective 
treatment of acute agitation was found for haloperidol, 
olanzapine and lorazepam. This recommendation is also 
supported in the NICE guideline on acute agitation [26]. 
The findings from our study point out that clinicians have 
a complex relationship with these guidelines. When they 
are asked to consider non-secluded and therefore mildly 
agitated patients, prescribing preferences are in line with 
published evidence. In contrast with this, when asked to 
consider secluded patients with evidently higher levels 
Table 4 Between group differences in secluded patients
Fisher’s exact test was performed when one of the two groups had at least 2 counts (2-sided).













Amisulpride 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Alprazolam 0 (0) 1 (2.7) – 2 (2.8) 4 (10.8) 0.178
Aripiprazole 3 (4.2) 1 (2.7) 1.000 4 (5.6) 1 (2.7) 0.659
Bromazepam 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Clonazepam 0 (0) 0 (0) – 1 (1.4) 1 (2.7) 1.000
Cloxazolam 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Clorazepaat 3 (4.2) 1 (2.7) 1.000 10 (14.1) 7 (18.9) 0.581
Clotiapine 16 (22.5) 7 (18.9) 0.806 31 (43.7) 16 (43.2) 1.000
Diazepam 0 (0) 6 (16.2) 0.001 6 (8.5) 20 (54.1) <0.001
Droperidol 13 (18.3) 3 (8.1) 0.253 28 (39.4) 11 (29.7) 0.400
Escitalopram 0 (0) 0 (0) – 0 (0) 0 (0) –
Haloperidol 3 (4.2) 1 (2.7) 1.000 10 (14.1) 14 (37.8) .007
Lamotrigine 0 (0) 0 (0) – 0 (0) 1 (2.7) –
Lorazepam 6 (8.5) 8 (21.6) 0.071 38 (53.5) 14 (37.8) 0.156
Midazolam 0 (0) 2 (5.4) 0.115 0 (0) 7 (18.9) <0.001
Olanzapine 17 (23.9) 6 (16.2) 0.460 34 (47.9) 9 (24.3) 0.023
Prazepam 0 (0) 0 (0) – 1 (1.4) 0 (0) –
Promethiazine 0 (0) 0 (0) – 1 (1.4) 3 (8.1) 0.115
Quetiapine 3 (4.2) 0 (0) 0.550 12 (16.9) 0 (0) 0.007
Risperidone 0 (0) 0 (0) – 2 (2.8) 1 (2.7) 1.000
Zuclopenthixol 0 (0) 0 (0) – 4 (5.6) 0 (0) 0.297
Zuclopenthixol LA 7 (9.9) 0 (0) 0.093 22 (31.0) 0 (0) <0.001
Sodium Valproate 0 1 (2.7) – 2 (2.8) 1 (2.7) 1.000
Paliperidone 0 0 – 1 (1.4) 0 (0) –
Pipamperone 0 0 – 1 (1.4) 1 (2.7) 1.000
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of agitation, the compliance with guidelines disappears 
and potent sedative drugs as clotiapine and droperidol 
emerge as a preferred choice.
It should be noted that zuclopenthixol is not a drug of 
choice for agitated patients since it does not meet the 
requirements of a drug used in rapid tranquillisation (i.e. 
onset of action within 20–30 min, maximum plasma con-
centration within 2 h, short half-life). However, the long 
acting form of zuclopenthixol is found to be well-favored, 
both in non-secluded as in secluded patients. This is not 
in line with earlier mentioned recent recommendations 
found in the literature [23, 24, 27] where long acting 
drugs have no place in the acute treatment of agitation 
and thus there is a clear need for education. The observa-
tion that some medications (e.g. escitalopram) are used 
which are not considered suitable for managing acute 
agitation is also of importance in this light.
An interesting finding is that a comparison between 
type of medical specialist produced significant differ-
ences in prescription preferences. Most notably, emer-
gency physicians prefer benzodiazepines most, both in 
secluded and in non-secluded patients. The analysis of 
these responses on the level of individual drugs shows 
that (1) no specific preference for benzodiazepines with 
shorter half life could be found (midazolam as well as 
diazepam are reported) and (2) that specifically psychia-
trists prefer antipsychotics as quetiapine (in all patients), 
olanzapine (in patients with higher levels of agitation) 
and long acting zuclopenthixol the most. This gives evi-
dence to support the hypothesis that both types of spe-
cialists use different strategies to treat acute agitation. To 
our knowledge, this distinction is never made in earlier 
prevalence studies although it seems relevant from our 
data to do so. It is known that psychiatrists and emer-
gency physicians have a different education with respect 
to psychotropic medication or use these drugs in other 
indications which may lead to a bias in selection prefer-
ence. Moreover, the content of the hospital formulary 
may differ between general hospitals and psychiatric 
hospitals, which could in turn also lead to the selection 
of different treatments. It can also be argued that the pur-
pose of rapid tranquillisation for the psychiatrist might 
be to effectively sedate the patient but without hampering 
further diagnostic actions, whilst an emergency doctor is 
primarily focused on controlling the disruptive behav-
iour. Finally, physicians—in Belgium—are approached 
with different pharmaceutical information by different 
pharmaceutical companies. It can be postulated that this 
practice also has an effect on which drug is prescribed, 
certainly in the context of our finding that most respond-
ents never use any published guideline.
The age of the prescribing physician also plays an 
important role. Older physicians prefer significantly more 
the use of the long acting form of zuclopenthixol when 
compared to their younger peers (in secluded patients). 
This could also be interpreted as an effect of education 
or changes in information strategies from pharmaceuti-
cal companies.
An explanation for our finding of a sparse use of moni-
toring—at least for assessment of efficacy of a treat-
ment—can be found in a recent systematic review by 
Zeller and colleagues who reported a similar observation 
[28]. The authors hypothesize that, although agitation is a 
common behavioural emergency, there is a lack of easy-
to-administer instruments that could improve treatment 
quality or predict treatment effects.
Our study has several limitations. The response rate is 
low, the definition of agitation that was used is not a clear 
clinical definition and there were no questions on how 
medication was delivered to the patient (per os, intra-
muscularly, intravenously).
Conclusion
There is no clear or systematic rationale for prescribing 
for acute agitation in Belgium. Practice in treating acute 
agitation shows a complex relation with published evi-
dence and guidelines. The level of agitation in patients 
and the type of physician prescribing the first pharma-
ceutical treatment both are clearly important variables 
and should be implemented in further research designs. 
A variety of causes can be put forward to explain this dif-
ference between both groups of physicians and this also 
warrants further research.
The high prevalence of the non-recommended use of 
zuclopenthixol acetate in the psychiatrist group raises 
concern and should be taken into account in future medi-
cal education. Moreover, it is of great concern that there 
is a substantial lack in the existence and in the use of 
assessment tools that measure the effect and safety of a 
treatment—preferably directly in the moment and in the 
patient and not post hoc by means of a measurement 
scale by a caregiver.
Note: Availibility of psychotropic drugs outside 
Belgium
Certain drugs mentioned in this study are bot avail-
able or in use in countries outside Belgium. Clotiapine 
is a dibenzothiazepine with ATC (Anatomical Thera-
peutic Chemical Classification) N05AH06, Bromazepam 
is a benzodiazepine with ATC (Anatomical Therapeutic 
Chemical Classification). N05BA08 and pipamperone is a 
bipiperidine with ATC (Anatomical Therapeutic Chemi-
cal Classification) N05AD05.
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